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Abstract
Allotransplantation of natural killer (NK) cells has been shown to be a key factor in the control and
cure of at least some hematologic diseases, such as acute myeloid leukemia or pediatric acute
lymphocytic leukemia. These results support the idea that stimulation of NK cells could be an
important therapeutic tool in many diseases, and several such approaches are now in clinical trials,
sometimes with conflicting results. In parallel, recent advances in the understanding of the molecular
mechanisms governing NK-cell maturation and activity show that NK-cell effector functions are
controlled by complex mechanisms that must be taken into account for optimal design of therapeutic
protocols. We review here innovative protocols based on allotransplantation, use of NK-cell
therapies, and use of newly available drug candidates targeting NK-cell receptors, in the light of
fundamental new data on NK-cell biology.
Introduction
Natural killer (NK) cells are the front-line troops of the
immune system that help to keep you alive while your
body marshals a specific response to viruses or malignant
cells. They constitute about 10% of circulating lympho-
cytes[1]andareonpatrolconstantly, alwaysonthelook-
out for virus-infected or tumor cells, and when detected,
they lock onto their targets and destroy them by inducing
apoptosis while signaling danger by releasing inflamma-
tory cytokines. By using NK cells that do not need prior
exposure to their target, the innate immune system buys
time for the adaptive immune system (T cells and B cells)
to build up a specific response to the virus or tumor.
Recentadvancesinunderstandingthisprocesshaveledto
the hope thatNK cells could beharnessed as atherapy for
cancers and other diseases, and we shall outline recent
progress in understanding NK-cell biology that brings
this approach into the realm of clinical trials.
Considerable advances have been made in understand-
ing the molecular mechanisms governing NK-cell activa-
tion, which are assessed by the cells’ ability to lyse
different targets and/or secrete inflammatory cytokines
such as interferon gamma (IFN-g)w h e ni nt h e i r
presence. NK-cell activation is the result of a switch in
the balance between the positive and negative signals
provided by two main types of receptors. The receptors
NKG2D, NKp46, NKp30, NKp44, the activating form of
KIR (killer cell immunoglobulin-like receptor), known as
KIR-S, and CD16 provide positive signals, triggering
toxicity and production of cytokines. Although some of
the ligands of these receptors remain unknown, the
discovery of NKG2D ligands (MICA and the RAET1
family) and the NKp30 ligand (B7H6) suggests that such
receptors recognize molecules that are seldom present on
normal cells but are induced during infection or
carcinogenesis. It is worth noting that CD16 recognizes
antibody-coated target cells through their Fc portion, the
receptor that mediates antibody-dependent cellular
cytotoxicity, an important mechanism of action of
therapeutic monoclonal antibodies (mAbs). The func-
tion of KIR-S, a family of activating receptors with a lot of
homology with inhibitory KIRs (KIR-L) including the
sharing of some ligands, remains largely unknown.
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balances to keep NK cells from attacking normal cells:
activating ligands are rare on normal cells and there are
inhibitory receptors on NK cells (Figure 1). The most
studied inhibitory receptors are a family of immunoglo-
bulin (Ig)-like receptors with two (KIR2DL1 and
KIR2DL2/3) or three (KIR3DL1) Ig-like domains, and
immunoreceptor tyrosine-based inhibition intracellular
motifs (ITIMs), which transduce negative signals [2]. The
ligands of these receptors are well characterized and each
consist of large families of major histocompatibility
complex (MHC) class I gene variants (alleles) sharing
structural determinants. KIR2DL1 and KIR2DL2/3 mole-
cules recognize MHC-C alleles with a lysine or an
asparagine at position 80 (collectively termed C2 alleles
and C1 alleles, respectively), whereas KIR3DL1 recog-
nizes MHC-B alleles sharing a Bw4 epitope, representing
about half of the overall MHC-B alleles. Another
receptor, NKG2A, recognizes HLA-E, an MHC class
I-like molecule, loaded mostly with peptides derived
from other class I molecules [3]. The expression of these
molecules is variegated, and an individual NK cell will
express either one or several inhibitory receptors. In
combination, these receptors are sensors of the presence
of MHC class I molecules on target cells and inhibitors of
NK function. An integrated, although simplified, view of
NK-cell activation is that NK cells quantitatively integrate
positive and negative signals provided by cancer cells or
infected cells, which express NK-stimulatory ligands
de novo, while often down-modulating MHC class I to
avoid detection by T cells.
There has beenconsiderable interestin stimulationofNK-
cell activity in recent years because of genetic studies, both
in preclinical and clinical settings, showing that it can
increase tumor immunosurveillance and eradicate estab-
lished hematological diseases such as acute myeloid
leukemia (AML), as well as some viruses [4]. In mouse
models,the expressionofNK-stimulatoryNKG2D ligands
not only induces short-term rejection of tumors, but also
induces a protective adaptive immune response [5].
Similarly, mice genetically deficient in NKG2D are more
susceptibletospontaneouscancerthanwild-typemice[6].
In humans, the development of allotransplantation, a
clinical procedure involving transplantation of genetically
nonidentical cells (routinely used in AML), shed light on
the role of NK cells and particularly the role of inhibitory
receptors in this process. For certain donor recipient pairs,
genetic differences in MHC class I genes between the
donor and the recipient cause the KIR-expressing cells
Figure 1. Natural killer (NK) cell recognition strategies
NK cells sense interacting cells via their activating and inhibitory receptors. The density of ligands for these receptors dictates whether or not this
interaction will lead to NK-cell activation and hence cytotoxicity and/or cytokine secretion. MHC, major histocompatibility complex; KIR, killer cell
immunoglobulin-like receptor.
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class I ligands in the recipient, leaving a subpopulation
of donor NK cells free from inhibition, referred to as
“alloreactive” NK cells. For example, a donor NK-cell
subpopulation expressing only KIR2DL1 transplanted in
C1/C1 homozygotes or KIR2DL2/3 NK cells transplanted
in C2/C2 individuals do not find their cognate inhibitory
ligands and become alloreactive. In haploidentical MHC-
mismatched hematopoietic stem cell transplantation
(HSCT)—a situationwhere oneMHC haplotype issimilar
between donor and recipient whereas the other is fully
mismatched—that absence of inhibition due to the KIR-
MHC incompatibility results in major differences in the
clinical outcome [7-9]. Clinical benefit correlates with the
presence in the recipient of these disinhibited alloreactive
NK cells from the donor, which are effective against
recipient tumor cells. In viral infections, particular
combinations of NK-activating receptors or KIR and their
ligands are protective. Presence of the activating receptor
KIR3DS1 and its putative ligand HLABw4-I80 has been
shown to be a key factor in preventing HIV infection from
leading to full-blown AIDS [10-12]. In hepatitis C,
KIR2DL3 homozygosity and HLA-C1 homozygosity are
beneficial in both early eradication of infection and
response to standard treatment (type I IFN + ribavirin)
[13,14]. Homozygosity of KIR2DL3 and HLA-C1 alleles
has been reported to lead to lower levels of NK inhibition
than other pairs of KIR ligand combinations [15,16],
suggesting that this underlies the enhanced response to
hepatitis C. However, as KIR can also be expressed by
some T-cell subsets, it remains to be firmly established
whether NK cells are responsible for these effects. Never-
theless, the results of these studies suggest that we should
extend the design of NK cell-based therapies to diseases
other than cancer, such as infections and inflammation.
We will review here the recent advances that could help
with the design of proper protocols and therapies and
advance the use of NK cells in the clinic, starting with
allotransplantation (transplantation between geneti-
cally different individuals o ft h es a m es p e c i e s ) .T h i s
will be followed by a discussion of the cell therapy
procedures that are being developed, and the pharma-
cological agents that are currently or could be used in
clinical trials to take advantage of the activity of NK
cells.
Lessons from transplantation
Since the initial data from haploidentical HSCT, a
number of retrospective studies in allostransplantation
have been published, sometimes leading to differing
clinical outcomes [17]. These conflicting results may be
explained in the light of new findings in NK-cell
physiology and maturation.
Initially, alloreactive NK cells were simply defined by
having KIRs that were only incompatible with the host
MHC, and several studies have identified such alloreac-
tive NK cells that are effective against AML blasts.
However, it has been shown in normal mice that NK
cells with only inhibitory receptors incompatible with
self MHC class I alleles do arise physiologically (i.e., not
after transplantation) but are partially functionally
disabled [18]. Hence, NK cells undergo a complex
maturation process that necessitates the interaction of
their inhibitory receptors with their ligands, in order to
be fully functional against class I negative cells (recogni-
tion of missing self; see [18] for review). The precise
molecular mechanisms and localization of this process
remain largely unknown in mice but were shown to be
dynamic and reversible [19,20]. It has since been
confirmed in humans that NK cells with only MHC-
incompatible KIR cells do exist in normal individuals
but, as in mice, they are partially functionally disabled
[21-22], indicating that human NK cells also undergo
education much like mouse NK cells. This leads to a
revision of the concept of alloreactivity: KIR mismatch is
necessary to induce activity against MHC-positive cells
(we will refer to these cells as potentially alloreactive) but
not entirely sufficient, as they must have undergone an
education process. It follows that functional assays must
be performed to demonstrate activity and define truly
alloreactive cells.
These new findings may lead to reconciliation of the
conflicting data from allogeneic HSCT. Allogeneic HSCT
(from a nonidentical donor) is a complex clinical
procedure, with considerable differences in the nature
and origin of the graft, as well as in pregraft treatments
(conducted to remove recipient hematopoietic cells and
thereby allow the graft to implant) and postgraft
treatments (to prevent graft-versus-host disease
[GVHD] caused by donor T cells). Generally, there are
two main scenarios. In the first, haploidentical grafts
consisting of high doses of highly purified donor CD34-
positive hematopoietic stem cells, with very few mature
cells, are injected after very intense conditioning
regimens of the host to avoid graft rejection (there is
virtually no postgraft treatment as the graft is highly
T cell-depleted) (Figure 2). Truly alloreactive NK cells
have been consistently found ex vivo following such
transplantation, in an activated state resulting from
missing-self recognition, and this scenario is associated
with an improved clinical outcome [23]. Unfortunately,
such haploidentical procedures also require profound
immunosuppression of the host, and the treatment-
related morbidities caused by infection are high, so such
procedures are not used widely. In the second scenario,
allogeneic HSCT can be matched except at a given HLA-B
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NK-cell recognition strategies can be manipulated in the context of hematopoietic stem cell transplantation (HSCT); (1) and (2) by infusion of pure,
activated NK-cell preparation and (3) by administration of antiKIR monoclonal antibodies (mAbs) (see text). MHC, major histocompatibility complex;
KIR, killer cell immunoglobulin-like receptor.
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pregraft, but more immunosuppressive treatment post-
graft to avoid GVHD. Such protocols vary widely
depending on the laboratories, both in terms of pregraft
and postgraft treatments and cell content in the graft
(mature cell content and origin of graft consisting of
either bone marrow cells or mobilized peripheral cells).
Not surprisingly, such protocols vary widely in the KIR
mismatch effect, with outcomes to match: beneficial,
neutral, or even pejorative. Taking into account the new
findings on NK-cell physiology, the current prevailing
hypothesis is that in haploidentical HSCT, the harsh
conditioning regimen and high CD34-positive cell
content allow the donor NK cells to mature with a
recognition of the “self” MHC type on the donor
hematopoietic cells, and therefore become truly allo-
reactive against residual recipient blast cells, whereas
normal host tissues are spared because of lack of
NK-stimulatory ligand expression [24,25]. In nonhaploi-
dentical situations, education of NK cells on donor HLA
may be lacking in some graft preparation and pregraft
regimens, which might account for the neutral effects
seen (cells remain potentially alloreactive). Conflicting
results in nonhaploidentical situations [26,27] may be
also explained by different treatments resulting in
different T-cell levels in grafts and consequently different
levels of GVHD [28]. This hypothesis is further
supported by protocols where the graft origin is cord
blood, a situation with few mature T cells in the graft,
which results in a beneficial outcome [29].
In truly matched transplantation, there are no obvious
reasons for alloreactive cells to develop as the MHC of
donor and recipient are the same and the maturation of
NK cells should spare all host cells (either normal or
NK-stimulating ligand-expressing cells). Surprisingly,
even in completely MHC-matched transplantation, in
particular in T-depleted grafts, functionally alloreactive
NK cells have been reported, with an improved outcome
for patients homozygous for HLA-C1 or HLA-C2, for
example [30,31]. In the same vein, it has been recently
demonstrated in a large retrospective study that the KIR
genotype alone influences clinical outcome, with the
presence of KIR2DL3 and/or absence of KIR2DL2 and
KIR2DS2 being less favorable, opening the way for the
selection of donors based on KIR genotype in matched
allotransplantation [32]. The functional basis of such
observations is still incompletely understood: during
NK-cell reconstitution from stem cells, KIR expression is
variegated, and potentially alloreactive cells appear, but,
as mentioned above, if such reconstitution was equiva-
lent to normal NK-cell maturation, they should be
functionally impaired and tolerant to self. It is possible
that during hematopoietic reconstitution and in certain
allograft protocols, the cytokine milieu, strength of
inhibitoryinteraction and presenceof different activating
genes (depending on KIR genotype), and absence of
T-cell interaction (T cell-depleted grafts) favor the
maturation of truly alloreactive NK cells despite the
presence of matched inhibitory receptors. Indeed, new
studies describing NK-cell maturation point to the fact
that the hyporesponsiveness of NK cells is very subtle
and malleable, influenced by cytokines and probably
genotype, and reversible [19,20].
In summary, although many studies strongly suggest the
efficacy of KIR-mismatched NK cells, definitive studies
are needed to optimize the clinical settings. We need a
better understanding of NK-cell development and func-
tion after matched allogeneic transplantation, depending
on the specific allotransplantation protocol used, to take
full advantage of the alloreactive potential of NK cells.
Cell therapy protocols in development
The current view arising from the results of allotrans-
plantation studies is that NK cells, and particularly
allogeneic KIR-mismatched NK cells, are effective, at least
in adult AML and pediatric acute lymphocytic leukemia,
but that the effect may depend on NK-cell maturation/
activation state. One way to better control NK-cell
functional status (as well as the ratio of NK cells to
target cells) would be to generate large quantities of these
cells in vitro and inject them either as a therapeutic
regimen alone or after allotransplantation.
Historically, crude, short-term (1–2 days) interleukin
(IL)-2-activated cells were used as graft material (lym-
phokine-activated killer [LAK] cells), and although this
was enriched in NK cells, the LAK cells were mostly T
cells, and the cellular content was poorly defined and
variable (see [33] for review). Initial attempts to work
with purified preparations of NK cells led to promising
results, although with a limited number of patients.
Autologous HSCT followed by injection of purified,
short-term IL-2-stimulated KIR-mismatched NK cells in
multiple myeloma patients destroyed multiple myeloma
blasts in vitro, did not lead to graft failure, and the NK
cells survived at least a few days [34]. In a protocol not
involving HSCT, purified short-term IL-2-activated hap-
loidentical NK cells were injected into AML and other
hematologic cancer patients after mild conditioning to
avoid rejection of injected NK cells. This study showed
that injected NK cells survived in the host for a few days
and were well tolerated [35]. Although the number of
patients is still too limited to draw firm conclusions,
encouraging clinical signs of activity were seen in the
above protocols. As neither protocol reached any dose-
limiting toxicity, these findings suggest that it may be
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ex vivo expansion procedures improve.
These initial results have prompted several groups to
embark on the large-scale expansion of highly purified,
GMP (“good manufacturing practice”) grade NK cells
after longer-term in vitro expansion. NK-cell purifica-
tion by magnetic beads is followed by IL-2 expansion
with or without feeder cells. Protocol for generation of
single KIR-positive cells has also been designed but is
not yet ready to be applied to large-scale clinical trials
[36]. Functional studies using NK cells against leuke-
mic cells or NK infusion in xenogenic models have
demonstrated, however, that the cells generated are
very active. Some of the protocols have reached small-
scale phase I clinical trials and have demonstrated that
high numbers of these infused NK cells are safe in
humans [37,38].
The current caveats of such protocols are the complexity
of the procedures required, which would make it
difficult to increase the scale-up to multicenter clinical
studies necessary for larger phase II trials. Indeed,
successful transfer of cell therapy protocols (compliant
with regulatory standards) to industry and large clinical
trials requires a centralized cell culture factory and the
use of frozen cells. NK-cell culture protocols do not yet
meet this benchmark, but further refinements should
solve these issues [39]. Moreover, alloreactive NK cells
should be the most potent cells in cell therapy protocol
and their source can be a problem outside the context of
allotransplantation. This alone may prevent the use of
such cells in larger trials. The development of antiKIR-
therapeutic mAbs (see below and Figure 2) that block
NK inhibition may allow the use of autologous cells as
an easier source of cell material, by inducing allor-
eactivity of NK cells that would otherwise be MHC-
tolerant.
Another important problem to be solved is the fate of
ex-vivo expanded NK cells after infusion. Indeed, if NK cells
fromallogeneicdonorsareused,theymayberejectedbythe
host immune system despite the mild immunosuppression
used in some protocols. Even in cases of autologous
transplantation or allotransplantation where donor NK
cells are not rejected, they may be short lived, and protocols
usually involve daily injection of IL-2 to sustain NK levels
and activation status [34,35]. IL-2 injection may increase
NK-cell lifespan and activity (although it has not been
formally tested, by comparison with untreated cells) but
also can generate outgrowth of Treg cells that may hamper
the overall response to the tumor as shown in pilot clinical
trials [37,40]. The very recent availability of GMP grade
IL-15, now in phase I clinical trials by the National Institutes
of Health (NIH) [40] may circumvent the use of IL-2,
providingabetteractivationsignalforNKcells,bothinvitro
and in vivo, without promoting Treg expansion.
Pharmacological agents in development to modulate
NK activity
Although cell therapy protocols can be very useful to
characterize NK-cell activity and, if successful, can
translate into commercially available products, they
remain very difficult and costly to develop on a large
scale. It should be easier to move new drugs forward now
that therapeutic agents are being tested that aim to
stimulate NK-cell activity.
The most advanced compound specifically targeting NK
cells is a blocking antiKIR mAb. This mAb, 1-7F9,
recognizes KIR2DL1, 2, and 3 and therefore blocks the
inhibition imposed by virtually all MHC class I C alleles,
allowing it to be tested in all patients whatever their KIR
and HLA genotypes. Building on the results of allotrans-
plantation in AML and multiple myeloma patients [41],
as well as preclinical data showing reconstitution of
NK-cell lysis of MHC-positive multiple myeloma and
AML blasts in vitro and in preclinical models [42],
clinical trials with 1-7F9 mAb in both diseases have been
initiated. Phase I results showed good tolerability in both
scenarios (Vey et al., manuscript in preparation), paving
the way for phase II trials that are now ongoing. While
the monoclonal 1-7F9 should be valuable to block the
inhibition of NK cells, other products are now available
that can enhance the activation of NK cells. One of the
most promising of these is IL-15, which is a key cytokine
for NK cells.
In the same vein, it has been shown by several groups
that certain drugs, already available in the therapeutic
arsenal, can increase the expression of NK-activating
ligands on the tumor, and therefore increase NK tumor
lysis in vivo. Initially, it was shown that some
chemotherapy (5-FU, Ara-C, cisplatin) and radiation or
ultraviolet therapy targeting the DNA damage pathway
can increase expression of the NK-stimulating ligand
NKG2D on tumor cells, and lead to enhanced NK lysis of
tumors [43]. More recently, new drugs targeting protea-
some inhibitors, such as bortezomib, which is now
registered for the treatment of multiple myeloma, have
also been shown to induce NK-stimulatory ligands
[44,45]. Finally, lenalidomide (Revlimid), a drug which
has been shown to be active in multiple myeloma and to
have promising preliminary results in other hematolo-
gical malignancies, has been shown, in addition to
having a direct antitumor effect, to upregulate NK-cell
function through induction of cytokines [46] and to
induce NK-stimulatory ligands on tumor cells.
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therapies [47,48], can also have inhibitory effects on
NK cells so their use must be carefully evaluated, but
their clinical availability opens the door to multiple
combination possibilities, either sequentially or con-
comitantly, with cell therapy and antiKIR antibodies.
Such combinations are beginning to be tested in the
clinic (phase I/II for antiKIR in combination with
lenalidomide, and cell therapies in combination with
bortezomib [39]).
Future directions
Since the initial demonstration that NK-cell therapies are
effective in some contexts, there has been a lot of
progress in refining protocols, as well as new approaches
such as the injection of highly purified, functionally
controlled NK cells. Also, new drugs allow the in-vivo
manipulation of NK cells by targeting their inhibitory
receptors or activating receptors (through drugs driving
the expression of ligands of activating receptors on
tumor cells). All these tools have now been developed to
a point where they can be tested in clinical trials either
alone or in combination. Because recent advances have
increased our understanding of NK maturation and
function, such clinical trials can now be monitored for
NK-cell activity and represent attractive possibilities to be
translated into successful treatments in the clinic.
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